Bicycle Therapeutics (BCYC) to Release Earnings on Tuesday

Key Points

• Bicycle Therapeutics (BCYC) is set to release its Q2 2025 earnings on August 5th, with expectations of a loss of ($0.95) per share and revenue of $9.43 million.
• The company's stock is currently trading at $8.61, showing a decline of 1.0%, with a market cap of $596.24 million.
• Analyst ratings vary significantly, with price targets ranging from $15.00 to $29.00 and an average target of $24.22, indicating a mostly positive outlook.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect Bicycle Therapeutics to post earnings of ($0.95) per share and revenue of $9.43 million for the quarter.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Bicycle Therapeutics had a negative net margin of 790.07% and a negative return on equity of 25.54%. The firm had revenue of $9.98 million during the quarter, compared to the consensus estimate of $8.67 million. On average, analysts expect Bicycle Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Bicycle Therapeutics Stock Down 1.0%

BCYC stock opened at $8.61 on Tuesday. Bicycle Therapeutics has a 12 month low of $6.10 and a 12 month high of $28.67. The firm has a market cap of $596.24 million, a P/E ratio of -2.74 and a beta of 1.41. The company's 50-day moving average price is $8.00 and its two-hundred day moving average price is $9.34.

Analyst Ratings Changes

Several brokerages recently issued reports on BCYC. Morgan Stanley set a $17.00 price target on shares of Bicycle Therapeutics and gave the company an "equal weight" rating in a report on Monday, May 5th. Barclays decreased their price target on shares of Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. JMP Securities decreased their price target on shares of Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating for the company in a research note on Friday, May 2nd. Needham & Company LLC restated a "buy" rating and set a $29.00 price target on shares of Bicycle Therapeutics in a research note on Friday, May 2nd. Finally, Royal Bank Of Canada decreased their price target on shares of Bicycle Therapeutics from $32.00 to $25.00 and set an "outperform" rating for the company in a research note on Thursday, July 17th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $24.22.

Institutional Trading of Bicycle Therapeutics

Institutional investors have recently made changes to their positions in the company. Millennium Management LLC boosted its holdings in shares of Bicycle Therapeutics by 156.5% in the 1st quarter. Millennium Management LLC now owns 453,428 shares of the company's stock worth $3,850,000 after buying an additional 276,671 shares during the last quarter. Woodline Partners LP purchased a new position in shares of Bicycle Therapeutics in the 1st quarter worth about $3,088,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Bicycle Therapeutics in the 1st quarter worth about $214,000. Institutional investors own 86.15% of the company's stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.